DOCSLIB.ORG

Friday, October 9, 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Friday, October 9, 2015 Friday, October 9, 2015 FRIDAY,OCTOBER 9, 2015 DAY-AT-A-GLANCE Time/Event/Location All locations in the Washington State Convention Center unless otherwise noted 7:00 am - 7:00 pm . .. .. .. .. .. ................................................................... 3 ASBMR Registration Open Atrium Lobby, Level 4 8:00 am - 9:30 am . .. .. .. .. .. ................................................................... 3 Gerald D. Aurbach Lecture Presentation of the William F. Neuman and Lawrence G. Raisz Awards Hall 4A 9:30 am - 10:00 am . .. .. .. .. .. ................................................................... 3 Friday Networking Break Atrium Lobby, Level 4 10:00 am - 11:00 am.. .. .. .. .. ................................................................... 3 Meet-the-Professor Sessions Rooms 6A-619 10:00 am - 11:30 am.. .. .. .. .. ................................................................... 4 Grant Writing Session: How to Connect Your Specific Aims to Your Hypotheses Room 606-607 10:00 am - 11:30 am.. .. .. .. .. ................................................................... 4 Highlights of the ASBMR 2015 Annual Meeting Hall 4A 11:00 am - 11:30 am.. .. .. .. .. ................................................................... 5 Networking Break Atrium Lobby, Level 4 11:30 am - 12:45 pm . .. .. .. .. ................................................................... 5 Symposium – Metabolism of Bone Cells Room 6B 11:30 am - 12:45 pm . .. .. .. .. ................................................................... 6 ASBMR/ECTS Symposium – Skeletal Consequences of Diabetes and Obesity Room 6E 12:45 pm - 1:15 pm. .. .. .. .. .. ................................................................... 6 Networking Break Atrium Lobby, Level 4 1:15 pm - 2:30 pm. .. .. .. .. .. ................................................................... 6 Concurrent Orals: Musculoskeletal Maintenance and Repair Room 6C 1:15 pm - 2:30 pm. .. .. .. .. .. ................................................................... 7 Concurrent Orals: Osteoarthritis and Other Joint Disorders Room 6B 1:15 pm - 2:30 pm. .. .. .. .. .. ................................................................... 8 Concurrent Orals: Regulation of Bone Mass Room 6A 1:15 pm - 2:30 pm. .. .. .. .. .. ................................................................... 9 Concurrent Orals: Sclerostin and Wnt Signaling Room 6E 1 2:30 pm - 3:00 pm. .. .. .. .. .. .................................................................. 10 Networking Break Atrium Lobby, Level 4 3:00 pm - 4:15 pm. .. .. .. .. .. .................................................................. 10 Plenary Symposium – Bone Marrow Microenvironment Hall 4A 4:15 pm - 4:30 pm. .. .. .. .. .. .................................................................. 11 Networking Break Atrium Lobby, Level 4 4:30 pm - 5:30 pm. .. .. .. .. .. .................................................................. 11 Oral Poster Presentations: Basic Room 6B 4:30 pm - 5:30 pm. .. .. .. .. .. .................................................................. 12 Oral Poster Presentations: Clinical Room 6E 4:30 pm - 5:30 pm. .. .. .. .. .. .................................................................. 14 Oral Poster Presentations: Translational Room 6C 5:30 pm - 7:00 pm. .. .. .. .. .. .................................................................. 16 Discovery Hall Open Discovery Hall - Hall 4BC 5:30 pm - 7:00 pm. .. .. .. .. .. .................................................................. 16 Welcome Reception & Plenary Poster Session Discovery Hall - Hall 4BC 5:30 pm - 7:00 pm. .. .. .. .. .. .................................................................. 42 Young Investigator, Diverse Member and New Member Reception Discovery Hall - Hall 4BC 7:15 pm - 8:00 pm. .. .. .. .. .. .................................................................. 42 Young Investigator Networking Hour Sheraton Seattle - Grand Ballroom A 7:15 pm - 9:45 pm. .. .. .. .. .. .................................................................. 42 Rare Bone Disease Working Group Room 608-609 7:15 pm - 10:00 pm. .. .. .. .. .. .................................................................. 43 Adult Bone and Mineral Working Group Room 606-607 7:15 pm - 9:30 pm. .. .. .. .. .. .................................................................. 44 Muscle and Bone Working Group Room 611-612 7:30 pm - 9:30 pm. .. .. .. .. .. .................................................................. 44 Bone Turnover Markers Working Group Room 613-614 2 ASBMR REGISTRATION OPEN 7:00 am - 7:00 pm Washington State Convention Center Atrium Lobby - Level 4 GERALD D. AURBACH LECTURE PRESENTATION OF THE WILLIAM F. NEUMAN AND LAWRENCE G. RAISZ AWARDS 8:00 am - 9:30 am Washington State Convention Center Hall 4A 8:00 am Bone, Fat and Energy Regulation Bruce Spiegelman, Ph.D. Dana-Farber Cancer Institute and Harvard Medical School, USA Disclosures: Bruce Spiegelman, None Friday NETWORKING BREAK 9:30 am - 10:00 am Washington State Convention Center Atrium Lobby - Level 4 MEET-THE-PROFESSOR SESSIONS 10:00 am - 11:00 am Washington State Convention Center Rooms 6A-619 Meet-the-Professor Session: Bone Biomechanics and Age-Dependent Changes Room 616 Sandra Shefelbine, Ph.D. Northeastern University, USA Disclosures: Sandra Shefelbine, None Meet-the-Professor Session: Bone Quality-Raman, FTIR, SAXS, BSEM: What Do These Acronyms Mean? Room 615 Eleftherios Paschalis, Ph.D. Ludwig Boltzmann Institute for Osteology, Austria Disclosures: Eleftherios Paschalis, None Meet-the-Professor Session: Communicating Benefits and Risks of Osteoporosis Treatment Room 6A E. Michael Lewiecki, M.D., FACP, FACE University of New Mexico School of Medicine, USA Disclosures: E. Michael Lewiecki, Amgen 13; Alexion 14; Radius Health 14; Lilly 13; Merck 13; AgNovos 14 Meet-the-Professor Session: Inflammatory Bone Loss Room 617 Deborah Novack, M.D., Ph.D. Washington University in St. Louis School of Medicine, USA Disclosures: Deborah Novack, None 3 Meet-the-Professor Session: Osteosarcopenia: Managing Frailty Room 618 This program is supported by an educational grant from Merck & Co., Inc. Neil Binkley, M.D. University of Wisconsin, Madison, USA Disclosures: Neil Binkley, None Meet-the-Professor Session: Skeletal Aging Room 619 Stavros Manolagas, M.D., Ph.D. Central Arkansas VA Healthcare System, University of Arkansas for Medical Sciences, USA Disclosures: Stavros Manolagas, None GRANT WRITING SESSION: HOW TO CONNECT YOUR SPECIFIC AIMS TO YOUR HYPOTHESES Sponsored by the ASBMR Membership Engagement and Education Committee. 10:00 am - 11:30 am Washington State Convention Center Room 606-607 A panel of experts made up of senior scientists will offer insights on how to write the specific aims section of a grant to clearly connect to your hypotheses. Panelists will review both basic and clinical grant examples and will compare and contrast the differences in these grant formats. Participants will also have the opportunity to break into small group discussions with senior scientists at tables labeled either ‘basic’ or ‘clinical’. This is a can’t-miss opportunity for researchers at any career stage who want to gain valuable insight into writing a grant and getting their research funded. Co-Chairs Stavroula Kousteni, Ph.D. Columbia University Medical Center, USA Disclosures: Stavroula Kousteni, None Melissa Kacena, Ph.D. Indiana University School of Medicine, USA Disclosures: Melissa Kacena, None 10:00 am Panelists Jane Cauley, Ph.D. University of Pittsburgh Graduate School of Public Health, USA Disclosures: Jane Cauley, None Louis Gerstenfeld, Ph.D. Boston University School of Medicine, USA Disclosures: Louis Gerstenfeld, None HIGHLIGHTS OF THE ASBMR 2015 ANNUAL MEETING 10:00 am - 11:30 am Washington State Convention Center Hall 4A This special session is of interest to all health professionals, first-time meeting attendees, young investigators, individuals new to the field, nurses, clinical research study coordinators, physical therapists and/or those seeking guidance in navigating through the extensive ASBMR program. Co-Chairs Joan Lappe, R.N., Ph.D. Creighton University, USA Disclosures: Joan Lappe, None 4 Betsy McClung, R.N., M.N. Oregon Osteoporosis Center, USA Disclosures: Betsy McClung, None 10:00 am Basic Science Meeting Overview Roland Baron, D.D.S., Ph.D. Harvard School of Medicine and of Dental Medicine, USA Disclosures: Roland Baron, None 10:45 am Clinical Science Meeting Overview John Bilezikian, M.D. Columbia University College of Physicians and Surgeons, USA Disclosures: John Bilezikian, None NETWORKING BREAK 11:00 am - 11:30 am Washington State Convention Center Atrium Lobby - Level 4 Friday SYMPOSIUM – METABOLISM OF BONE CELLS This program is supported by an educational grant from Merck & Co., Inc. 11:30 am - 12:45 pm Washington State Convention Center Room 6B Co-Chairs Gerard Karsenty, M.D., Ph.D. Columbia University, USA Disclosures: Gerard Karsenty, None Ernestina Schipani, M.D., Ph.D. University of Michigan, USA Disclosures: Ernestina Schipani, None 11:30 am Angiogenesis Revisited: Endothelial Cell Metabolism as a Target? Peter Carmeliet, M.D., Ph.D. University of Leuven, Belgium Disclosures: Peter Carmeliet, None 11:55 am Osteoclast Metabolism Kyoji Ikeda, M.D. National Center for Geriatrics and Gerontology, Japan Disclosures: Kyoji Ikeda, None 12:20 pm The Bioenergetics of Bone Thomas Clemens, Ph.D. Johns Hopkins University, USA Disclosures: Thomas Clemens, None
Load more

Recommended publications
  • Annual Report 2020 | 3 Item Source Summary of Reporting Requirement Page No
    For the year ended 31 December 2020 Contents Page Disclosure Index 3 Section A – Overview 7 Chancellor Statement 8 Vice-Chancellor Statement 9 COVID-19 Response 10 About the University 12 Vision and Mission 15 Strategic Plan 2025 16 Section B – Governance 19 The University Council 22 Academic Board 26 Financial Performance 28 Fees 32 Compliance 34 Section C – University Activities 39 Students 40 Staff 47 Office of the Vice-Chancellor 50 School of Graduate Research 51 Research 52 Libraries 54 University Networks 55 Responding to the Royal Commission 57 Donations 59 Section D – Colleges 60 Australian Lutheran College 61 Catholic Theological College 62 Eva Burrows College 63 Jesuit College of Spirituality 64 Morling College 65 Pilgrim Theological College 66 St Athanasius College 67 Stirling Theological College 68 Trinity College Theological School 69 Whitley College 70 Yarra Theological Union 71 Section E – Financial Statements 72 Financial Statements 73 Certification 106 Auditor’s Report 107 Auditor’s Declaration 109 2 | University of Divinity The annual report of the University of Divinity is prepared in accordance with: AASB Australian Accounting Standards Board ETRA Education and Training Reform Act 2006 FMA Financial Management Act 1994 FRD Financial Reporting Directions SD Standing Directions 2018 Under the Financial Management Act 1994 Item Source Summary of Reporting Requirement Page No. Number REPORT OF OPERATIONS CHARTER AND PURPOSE 1. FRD 22H Manner of establishment and the relevant Minister 12; 99 5.4 a 2. FRD 22H Purpose, functions, powers and duties linked to a summary of 8-18 5.4 b activities, programs and achievements 5.5 3.
    [Show full text]
  • Are Nanodiamond-Encrusted Teeth the Future of Dental Implants? 18 September 2013, by Brianna Deane
    Are nanodiamond-encrusted teeth the future of dental implants? 18 September 2013, by Brianna Deane prosthetic joints or teeth, which leads to the implants becoming loose—or failing. Implant failures necessitate additional procedures, which can be painful and expensive, and can jeopardize the function the patient had gained with an implant. These challenges are exacerbated when the disease occurs in the mouth, where there is a limited supply of local bone that can be used to secure the prosthetic tooth, a key consideration for both functional and aesthetic reasons. The study, led by Dr. Dean Ho, professor of oral biology and medicine and co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry, Nanodiamonds. Credit: UCLA School of Dentistry appears online in the peer-reviewed Journal of Dental Research. During bone repair operations, which are typically (Medical Xpress)—UCLA researchers have costly and time-consuming, doctors insert a sponge discovered that diamonds on a much, much through invasive surgery to locally administer smaller scale than those used in jewelry could be proteins that promote bone growth, such as bone used to promote bone growth and the durability of morphogenic protein. dental implants. Ho's team discovered that using nanodiamonds to Nanodiamonds, which are created as byproducts deliver these proteins has the potential to be more of conventional mining and refining operations, are effective than the conventional approaches. The approximately four to five nanometers in diameter study found that nanodiamonds, which are invisible and are shaped like tiny soccer balls. to the human eye, bind rapidly to both bone morphogenetic protein and fibroblast growth factor, Scientists from the UCLA School of Dentistry, the demonstrating that the proteins can be UCLA Department of Bioengineering and simultaneously delivered using one vehicle.
    [Show full text]
  • 2019-2020 UCLA Academic Senate Program Review of University Extension
    2019-2020 ACADEMIC SENATE PROGRAM REVIEW OF UNIVERSITY EXTENSION Internal Reviewers Olga T. Yokoyama, Humanities, Graduate Council, Review Team Chair Simon Board, Economics, Undergraduate Council External Reviewers Susan Greenbaum, Dean, Professional Studies, New York University John LaBrie, Dean, Professional Studies, Clark University Date of Site Visit: January 14-15, 2020 Approved by Undergraduate Council: April 10, 2020 Approved by Graduate Council: May 1, 2020 Appendix I: External Reviewers’ Report Appendix II: Site Visit Schedule Please note: The Self-Review report was previously distributed. If you need a copy, please contact the Academic Senate Office at [email protected]. 2019-2020 ACADEMIC SENATE PROGRAM REVIEW OF UNIVERSITY EXTENSION Introduction This report of the Internal Review Team for the 2019-2020 review of University Extension (UNEX) follows eight years after the prior Academic Senate Program Review of UNEX in 2011-2012. The current review draws primarily on a two-day site visit held on January 14-15, 2020, the prior Academic Senate Program Review Report from 2011-2012, the UNEX self-review of 2019, and the Huron Report of 2018; for the figures and other specific information, we relied on the Self- Review report and other data provided by the Academic Senate. We concur with the previous two reports in that “this is a somewhat daunting task, because of the sheer size of the UNEX enterprise”. This review comes at a time of transition. The new Dean Eric Bullard began his appointment in January of 2020, a week before our visit. At this time, neither of the two Associate Dean positions had been filled.
    [Show full text]
  • Protocol Supplementary
    Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf.
    [Show full text]
  • Board Member Profiles 2021
    PALOS VERDES PENINSULA LAND CONSERVANCY BOARD MEMBER PROFILES 2021 OFFICERS Carolynn Petru Occupation: City Administrator/Urban Planner – Retired 2015 President Community Activities: Peninsula Village, Board of Directors and Volunteer Awards & Distinctions: BS Environmental Planning, University of California, Davis; MA Urban Planning, University of California, Los Angeles; American Institute of Certified Planners (1996 – 2015) Rob Kautz Occupation: Principal, HollowayKautz Investments LLC Vice President Community Activities: Los Angeles Police Foundation, Vice Chair 2010-2011, Finance Finance Chair/Treasurer 2002-2010; East Los Angeles College Finance Club speaker/advisor, 2010; Haverford College Alumni Executive Committee 2006-2008; GE Capital Restaurant Leadership Forum, Advisory Board Member 2001-2005; volunteer lecturer on leadership and entrepreneurship, UCLA and Haverford College Awards & Distinctions: LA Business Journal CFO of the Year Finalist, 2010; Robert Half CFO Panel, 2006; National Association for Strategic Planning, Keynote Speaker 2003; National YPO Food and Beverage Roundtable, Keynote Speaker 2003; UCLA Extension/CA Restaurant Association panel 2002; GE Capital’s Innovative Concept of the Year, Award Recipient and Speaker 2002; MBA, Harvard Business School; BA, Economics Diana Bailey Occupation: Attorney – Retired 2015 Secretary Community Activities: Pro Bono, Public Counsel; Volunteer and Member of White Point Community Group and Home Tour, PVPLC; Board of Directors and Volunteer, National Charity League; Executive Board, PTA Rick Wallace Occupation: Certified Public Accountant Treasurer Community Activities: White Point Community Group; LA Biomed Finance Committee; City of Rancho Palos Verdes Finance Advisory Committee 2000-2006; South Bay Lacrosse Association Co-Founder/Chief Financial Officer 2002- 2010; Boy Scout Troop 783 Assistant Scoutmaster 1999-2002 PALOS VERDES PENINSULA LAND CONSERVANCY BOARD MEMBER PROFILES 2021 DIRECTORS Bill Ailor Occupation: Aerospace Fellow, The Aerospace Corp.
    [Show full text]
  • Enzymatic Assay of L-METHIONINE GAMMA-LYASE (EC 4.4.1.11)
    Enzymatic Assay of L-METHIONINE GAMMA-LYASE (EC 4.4.1.11) PRINCIPLE: L-Methionine Gamma-Lyase L-Methionine > Methanethiol + 2-Ketobutyrate + NH3 2-Ketobutyrate + MBTH > Azine Derivative Abbreviation used: MBTH = 3-Methyl-2-Benzothiazolinone CONDITIONS: T = 37°C, pH = 8.0, A320nm, Light path = 1 cm METHOD: Stopped Spectrophotometric Rate Determination REAGENTS: A. 100 mM Potassium Phosphate Buffer with 25 mM L-Methionine and 0.01 mM Pyridoxal 5-Phosphate, pH 8.0 at 37°C1 (Prepare 100 ml in deionized water using Potassium Phosphate, Monobasic, Anhydrous, Sigma Prod. No. P-5379, L-Methionine, Sigma Prod. No. M-9625, and Pyridoxal 5-Phosphate, Sigma Prod. No. P-9255. Adjust to pH 8.0 at 37°C with 5 M KOH.) B. 50% (w/v) Trichloroacetic Acid Solution (TCA) (Prepare 5 ml in deionized water using Trichloroacetic Acid, 6.1 N Solution, approximately 100% (w/v), Sigma Stock No. 490-10.) C. 1 M Sodium Acetate Buffer, pH 5.0 at 37°C (NaOAC) (Prepare 100 ml in deionized water using Sodium Acetate, Trihydrate, Sigma Prod. No. S-8625. Adjust to pH 5.0 at 37°C with 5 M HCl.) D. 0.1% (w/v) 3-Methyl-2-Benzothiazolinone Hydrazone (MBTH) (Prepare 10 ml in deionized water using 3-Methyl-2-Benzothiazolinone Hydrazone, Hydrochloride Hydrate, Sigma Prod. No. M-8006.) SSMETH01 Page 1 of 4 07/29/98 Enzymatic Assay of L-METHIONINE GAMMA-LYASE (EC 4.4.1.11) REAGENTS: E. 100 mM Potassium Phosphate Buffer with 1 mM Ethylenediaminetetraacetic Acid, 0.01% (v/v) 2-Mercaptoethanol and 0.02 mM Pyridoxal 5-Phosphate, pH 7.2 at 37°C (Enzyme Diluent)1 (Prepare 10 ml in deionized water using Potassium Phosphate, Monobasic, Anhydrous, Sigma Prod.
    [Show full text]
  • Lyxumia Subcutaneous Injection 300 Μg [Non-Proprietary Name] Lixisenatide (JAN*) [Name of Applicant] Sanofi K.K
    Report on the Deliberation Results May 31, 2013 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Lyxumia Subcutaneous Injection 300 μg [Non-proprietary name] Lixisenatide (JAN*) [Name of applicant] Sanofi K.K. [Date of application] June 11, 2012 [Results of deliberation] In the meeting held on May 24, 2013, the First Committee on New Drugs concluded that the product may be approved and that this result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The re-examination period for the product is 8 years, and the drug substance and the drug product are both classified as powerful drugs and the product is not classified as a biological product or a specified biological product. The proposed Japanese brand name should be changed for ensuring medical safety. *Japanese Accepted Name (modified INN) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Review Report May 7, 2013 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product submitted for registration are as follows. [Brand name] Lyxumia Subcutaneous
    [Show full text]
  • Maritime Trade and Merchant Shipping: the Shipping/Trade-Ratio from the 1870S Until Today
    INSTITUTT FOR SAMFUNNSØKONOMI DEPARTMENT OF ECONOMICS SAM 12 2016 ISSN: 0804-6824 June 2016 Discussion paper Maritime trade and merchant shipping: The shipping/trade-ratio from the 1870s until today BY Jari Ojala AND Stig Tenold This series consists of papers with limited circulation, intended to stimulate discussion. Maritime trade and merchant shipping: The shipping/trade-ratio from the 1870s until today Jari Ojala, University of Jyväskylä Stig Tenold, Norwegian School of Economics This paper discusses the development of countries’ market shares in world shipping over the last 150 years. The analysis is based upon a new and purpose-built indicator: the shipping/trade-ratio. This indicator presents the relationship between the merchant marine of a country and the country’s role in world trade. Analysis of the shipping/trade-ratio identifies two important developments. First, although the share of the world fleet registered in Europe has dropped significantly, Europe’s role in world shipping over the last fifty years has been more stable than is commonly perceived. Second, there appears to have been an increasing specialisation in the world shipping industry, both among and within continents. Internationally and within Europe, certain “super-transporters” have acquired large market shares, while most countries have relatively limited fleets. “The sea-shore has been the point of departure, to knowledge, as to commerce. The most advanced nations are always those who navigate the most.”1 Introduction Within naval history, the question of “maritime power” plays an important role. Countless books have been written and numerous careers have been forged trying to define, discuss and debate the question of what constitutes maritime power and who the maritime powers are and have been.2 Within merchant shipping history, the power question has seldom been explicitly discussed, though it has been an implicit element of national historical narratives.
    [Show full text]
  • Msx-1 Is Suppressed in Bisphosphonate Exposed Jaw Bone
    Msx-1 is suppressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Philipp Stockmann, Karl Andreas Schlegel, Friedrich Wilhelm Neukam, Emeka Nkenke To cite this version: Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Philipp Stockmann, et al.. Msx-1 is sup- pressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling. Oral Diseases, Wiley, 2011, 17 (4), pp.433. 10.1111/j.1601-0825.2010.01778.x. hal-00618503 HAL Id: hal-00618503 https://hal.archives-ouvertes.fr/hal-00618503 Submitted on 2 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Oral Diseases - Manuscript Copy Oral Diseases - Manuscript Copy Msx-1 is suppressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling Journal: Oral Diseases Manuscript ID: ODI-02-10-OM-1552.R1 Manuscript Type: Original Manuscript Date Submitted by the 07-Oct-2010 Author: Complete List of Authors: Wehrhan, Falk; University of Erlangen-Nürnberg,
    [Show full text]
  • Efficacy and Safety of Elcatonin in Postmenopausal Women with Osteoporosis: a Systematic Review with Network Meta-Analysis of Randomized Clinical Trials
    Osteoporosis International (2019) 30:1723–1732 https://doi.org/10.1007/s00198-019-04997-6 REVIEW Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials W.-C. Chen1,2 & E.-Y. Lin3 & Y.-N. Kang1,4 Received: 20 November 2018 /Accepted: 21 April 2019 /Published online: 1 May 2019 # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 Abstract Summary The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination thera- pies of elcatonin (C-E). Introduction Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. Methods This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they indepen- dently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. Results Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-elcatonin medications had comparable fracture rates and bone mineral density change.
    [Show full text]
  • The Un-Design and Design of Insulin: Structural Evolution
    THE UN-DESIGN AND DESIGN OF INSULIN: STRUCTURAL EVOLUTION WITH APPLICATION TO THERAPEUTIC DESIGN By NISCHAY K. REGE Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Biochemistry Dissertation Advisor: Dr. Michael A. Weiss CASE WESTERN RESERVE UNIVERSITY August, 2018 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Nischay K. Rege candidate for the degree of Doctor of Philosophy*. Committee Chair Paul Carey Committee Member Michael Weiss Committee Member Faramarz Ismail-Beigi Committee Member George Dubyak Date of Defense: June 26th, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication This thesis is dedicated to my mother, Dipti, whose constant love and faith have never failed, to my father, Kiran, who taught me of the virtue of curiosity, and to my wife, Shipra, whose kindness and companionship have given me enough strength for eight lifetimes. i Table of Contents Dedication ..................................................................................................................................... i Table of Contents ......................................................................................................................... ii List of Tables ............................................................................................................................... v List of Figures ...........................................................................................................................
    [Show full text]
  • HELD on 17.03.2012:- the NDAC (Analgesics, Anesthetics
    1. RECOMMENDATIONS OF THE NDAC (ANALGESICS, ANESTHETICS AND RHEUMATOLOGY) HELD ON 17.03.2012:- The NDAC (Analgesics, Anesthetics and Rheumatology) deliberated the proposals on 17.03.2012 and recommended the following:- AGENDA NAME OF DRUG RECOMMENDATIONS NO. New Drugs The firm has requested for 3 indications viz mild to moderate pain, dysmenorrhoea and rheumatoid arthritis and osteoarthritis. Committee recommended that the firm should conduct double blind comparative clinical study of Meclofenamate sodium with diclofenac (100mg/day) in 4 sites distributed geographically in the country. 50% of the sites should be in multispeciality hospitals 1 Meclofenamate which have their own Institutional Ethics Sodium Committee. Ethics Committee approval should be from the same area where the site is located. The firm should submit protocol etc. to the office of DCGI and DCGI may issue approval to the study. Based on the data generated, committee may consider their proposal for the three indications proposed. Committee considered the protocol for conduct of local clinical trial in Indian 2 Flupirtine-D- population. However protocol etc. should be Gluconate forwarded to the members for evaluation and recommendation to DCG(I). Committee recommended for approval of the drug in the country subject to submission of CDTL test report to DCG(I). Phase IV clinical trial should be conducted on 500 patients 3 Apixaban within 2 years. Protocol for the Phase IV trial should be submitted to DCG(I) within 3 months of approval of the drug which can be considered and approved by DCG(I). In view of cardiovascular safety concern, committee recommended for giving 4 Dexmedetomidine permission to conduct the study subject to condition that the study should be conducted in subjects aged 8 years and above.
    [Show full text]